825-51-4

Applied Filters:

Keyword:'825-51-4'

Showing 1-1 of 1 result for "825-51-4" within Papers

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.

S W Lam et al.

European journal of cancer (Oxford, England : 1990), 50(18), 3077-3088 (2014-12-03)

The addition of bevacizumab to paclitaxel or capecitabine has demonstrated improved progression-free survival (PFS) and objective response rate (ORR) as compared with chemotherapy alone in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). We evaluated the efficacy and

Page 1 of 1